Agenda ⇽ BioTrinity 2022 | OBN (UK) Ltd‌ on Glue Up

Tuesday, April 26, 2022 9:15^AM to 5^PM

9:25^AM - 9:30^AM

Welcome to BioTrinity's Science Track
Jonathan Rohll

Jonathan Rohll
Head of Business Information at OBN (UK) Ltd‌
Jonathan joined OBN in early 2012. He carries out a number of analytical tasks related to the Life Sciences sector in Oxford, the Thames Valley and the UK Life Sciences sector in general. More widely he performed a key role in OBN’s involvement in the work of the Oxford node of the FP7 HealthTIES project. Jonathan is also involved with the realisation of the OBN Consultancy service including cluster mapping, product searches and consultation responses.

Prior to joining OBN he carried out academic research in a number of areas including cell division, virology and immunology and moved to Oxford BioMedica in 1997 where he played a major role in the development of their lentiviral gene therapy ‘system’ for use in treatment of a variety of indications.
More information about speaker

9:30^AM - 9:50^AM

Keynote Scientific Update: Oncology
Etleva Pashaj

Sponsored by Sanofi

Guy Griebel
Head External Innovation Rare and Neurological Disorders at Sanofi
Laurent Pradier
Director Scientific Strategy and External Relations, Rare and Neurological Disorders of Sanofi

2^PM - 2:50^PM

Company Showcase Presentations: CNS
Jenny Barnett•Peter Hamley•Farid Khan•David Reynolds•Mo Shahid

Jenny Barnett
CEO of Monument Therapeutics
Peter Hamley
CSO at Samsara Therapeutics
Farid Khan
CEO of PharmaKure
David Reynolds
CEO of LoQus23 Therapeutics Ltd
Mo Shahid
CEO of Pheno Therapeutics

2:50^PM - 3:10^PM

Keynote Scientific Update: Infectious Disease
Helen Fletcher

Helen Fletcher
Scientific Innovation Lead, Global Public Health at Johnson and Johnson Innovation - JJDC
Helen Fletcher, PhD
Leader of the Johnson & Johnson Centers for Global Health Discovery (CGHD) and Scientific Innovation Lead for Global Public Health R&D (EMEA and Asia Pacific)

Helen Fletcher is the Leader of Johnson & Johnson Centers for Global Health Discovery (CGHD), a network of J&J operated labs being established in major public health institutions across the world, and Scientific Innovation Lead for Global Public Health R&D (EMEA and Asia Pacific).

As Scientific Innovation Lead, Helen will work in close collaboration with discovery scientists, business development, and Johnson & Johnson Innovation colleagues building new external innovation partnerships as well as identifying funding and public financing opportunities help build the discovery and R&D portfolio within J&J Global Public Health.

Before joining Johnson & Johnson Helen was a Professor of Immunology and Associate Dean of the Faculty of Infectious and Tropical Diseases at the London School of Hygiene & Tropical Medicine (LSHTM). Helen has a B.SC. and Ph.D. in Microbiology from the University of Leeds and more than 20 years’ experience in vaccine development from pre-clinical to phase I and II safety studies and clinical efficacy trials at University College London, University of Oxford and LSHTM.
More information about speaker

3:10^PM - 4^PM

Company Showcase Updates: Infectious Disease
Douglas Thomson•Peter Jackson•Anna Obolensky•Frederic GARZONI•Will Wjinberg

Douglas Thomson
CEO of Pneumagen
Peter Jackson
CEO of Infex Therapeutics
Anna Obolensky
Director,Translational Research of PGTx
Frederic GARZONI
CEO of Imophoron Ltd
Will Wjinberg
Executive Director of Matoke Holdings

Tuesday, April 26, 2022 9:45^AM to 4:20^PM

9:55^AM - 10^AM

Welcome to BioTrinity
Huw Jones

Huw Jones
CEO of Evgen Pharma Plc
Huw joined the OBN Board in April 2022. He has been CEO of Evgen Pharma PLC, a clinical stage cancer and inflammation company, since October 2020. Huw recently led the raise of £10m in a placing and up to a further £1m in an open offer in a transformative deal for Evgen. He is also a non-executive director of Ixaka Ltd (formerly Rexgenero) a cell and gene therapy company with operations in London, Paris and Seville; Non-executive Chairman of Chronos Therapeutics Ltd in Oxford, and strategic advisor to Gen2 Neuroscience in Cambridge, an antibody company focussed on tauopaties such as Alzheimer’s Disease.
More information about speaker

10^AM - 10:30^AM

Keynote: A Review of the Life Sciences Investment Landscape
Tim Haines

Join us for this opening session of BioTrinity 2022, where Tim Haines will be sharing his expert insight into the key factors shaping investment in the life sciences industry, what this means to companies, challenges encountered and key areas of opportunity.

Tim Haines
Chairman and Managing Partner at Abingworth LLP

10:30^AM - 11:30^AM

Interview: Inspiring Innovators
Harry Destecroix•Jason Mellad•Emma Palmer Foster

This hour-long session will feature two interviews with life sciences entrepreneurs/business leaders who have achieved success, but will reflect on the highs, lows, and challenges they have experienced and overcome throughout their career. The interviews will look at all aspects of business success, not just the science, but team and Board, investment, strategy, stages of growth, location, culture, and your place in the wider business ecosystem.

Emma Palmer Foster will be Interviewing Harry Destecroix, Co-Founder, Science Creates & Jason Mellad, CEO Start Codon

Harry Destecroix
General Partner & Co-Founder of Science Creates Ventures
Jason Mellad
CEO of Start Codon
Emma Palmer Foster
Strategic Communications Consultant at The Oxford Science Park

11:50^AM - 12:30^PM

Keynote: How Will the Government's Life Sciences Vision Impact Your Business?
George Freeman•James Tumbridge

George Freeman
Minister for Life Science at Department for Business Innovation & Skills (BIS)
George Freeman is Minister for Science, Research and Innovation at the Department for Business, Energy & Industrial Strategy.

Elected to Parliament in 2010 after a 15-year career founding high-growth technology companies, George has served in the last three Governments as UK Trade Envoy, the first UK Minister for Life Science, Chair of the No10 Policy Board and Minister of State at the Department for Transport.

Most recently, he led the Prime Minister’s Task Force on Innovation, Growth and Regulatory Reform (TIGRR).

He is Founder of the Big Tent Festival and Foundation, the Reform for Resilience Global Health Commission and the 2020 Conservatives Group. He is also author of Britain Beyond Brexit and the former Chair of the Conservative Policy Forum.
More information about speaker
James Tumbridge
Partner, Barrister at Venner Shipley Intellectual Property
James is an Intellectual Property Litigation partner with Venner Shipley, a European firm focused on intellectual property advice. He has extensive experience in all science fields affected by intellectual property, and his practice has covered a wide variety of IP disputes, and ancillary issues affecting intellectual property rights. He has extensive experience in life science and has been involved in cases such as the House of Lords decision in RPR v Yeda concerning patent entitlement to a combination therapy for the treatment of cancer, and advice to Imperial College concerning their Covid-19 vaccine development. James’ work also extends to compliance in regards to data protection, especially the use of medical data for development of medical devices and treatments, in part because he was one of the authors of the Data Protection Act that implemented the GDPR, and on which subject he has lectured at the Texas Medical Center. He has been an ad hoc advisor to various UK MPs and MEPs on a range of IP and dispute issues, and advised MEPs on patent issues with vaccine development and delivery during the Covid pandemic. Through his engagement with policy makers he has extensive Government relations experience and advises clients on how to prepare for legislative changes and regulation compliance.
More information about speaker

12:30^PM - 1:30^PM

Lunch & Networking

2:20^PM - 3:20^PM

Panel Discussion: How do the Global Capital Markets Compare?
Laia Crespo•Sinclair Dunlop•Simon Haworth•Ian Oliver•Jasper Bos

Investors based in New York, London, and European centres are all highly active in seeking investable opportunities across national boundaries, but how do they vary in their approaches and what are the respective merits of dealing in a particular territory?

Our high-quality and experienced presenters will cover a range of issues to provide practical guidance on the available benefits and options including;
• Appetite to risk
• Investor sentiment
• Analytical capability to assess opportunities
• Acceptance of failure
• Liquidity considerations
• Tax benefits and implications
• Openness to international businesses
• Differing investment philosophies
• Optimising pitching approaches
• Impact on exit vehicles – route to subsequent IPO

Laia Crespo
Partner at Sanofi Ventures
Sinclair Dunlop
Co-Founder & Managing Partner of Epidarex Capital
Simon Haworth
CEO of Intelligent OMICS Limited
Ian Oliver
Partner at BDO LLP
Jasper Bos
General Partner at Forbion

3:20^PM - 4:20^PM

Panel Discussion: How will the latest Clinical Trial Design Strategies Impact Innovation?
Catherine Beech•Antimo Fiorillo•Javier Jimenez•Emma Tinsley•Helen Underwood

Sponsored by Thermo Fisher Scientific

Innovation in clinical trial design is transforming evidence generation in drug development, focusing on the effectiveness of clinical trials whilst maintaining high quality data for regulatory decision-making. Our expert speakers will expand on the advantages of the different approaches to help you identify the best and most cost-effective trials strategies for your business, including:

• Adaptive designs allowing trial modifications
• Master protocols designed to address questions in multiple diseases
• Enrichment designs tailoring treatments to those patients who will benefit most
• Umbrella Trials evaluating multiple investigational drugs administered as combinations
• Basket Trials studying a single therapy in multiple diseases or disease subtypes
• Platform Trials evaluating multiple therapies in a single disease in an open-ended format
• Historical control, where old data is used to compare with new data from new trials

Catherine Beech
CEO of Exonate Limited
Antimo Fiorillo
Founder & CEO of Allyfe
Javier Jimenez
EVP Transformational Design at Syneos Health
Emma Tinsley
CEO of Weatherden
Helen Underwood
Director, Strategic Client Relationships of Fisher Clinical Services UK

Wednesday, April 27, 2022 10^AM to 3:10^PM

10^AM - 10:30^AM

Fireside Chat: An Overview of Future Investment Trends in Life Sciences
Rafaèle Tordjman

During this session, Paul Edwards, Board Member of OBN will interview Dr Rafaele Tordjman, CEO of Jeito on a range of matters including:

• A broad update on Life Sciences investment trends and projections in Europe
• How has your investment philosophy evolved – and is this reflected in the wider industry?
• What are the typical timelines to exit and is this changing?
• What aspects are particularly attractive to investors?

Rafaèle Tordjman
Founder & CEO of JEITO

10:30^AM - 11^AM

Keynote: A Life Sciences Regulatory Update
Alison Dennis

This Keynote will provide insight on the major developments in UK policy and regulation in life sciences – to include areas such as tax, use of data, clinical trial testing of medicines, and the use of artificial intelligence tools and medical devices.

Alison Dennis
Partner at Taylor Wessing

11^AM - 12^PM

Panel Discussion: Trends, Opportunities and Support in the US Market
Rose Adedeji•John Catravas•Charles Macdowell•Matthew Segall•Hannah Williams

This session will feature a broad update on a range of matters, all useful for UK companies seeking growth opportunities in the US bio market, including:
• How to leverage academic and R&D services to boost your capabilities and offering to the industry
• how to secure the right talent and regional know-how to help support growth and maximise opportunities for your growing business
• Practical and up-to-date advice from the Department of Industry & Trade
• real-life case study insight into the opportunities and challenges involved in a move into the US Market, from a company owner who has first-hand experience

Rose Adedeji
US Expansion Advisor at Foothold America
John Catravas
Professor at Old Dominion University, Virginia
Charles Macdowell
Business Development Representative at VA Beach Bio
Matthew Segall
CEO of Optibrium
Hannah Williams
Deputy Head of Life Sciences at Department for International Trade

12:35^PM - 1:35^PM

Lunch & Networking

1:40^PM - 2:10^PM

Keynote: Maximising the Benefits of R&D Tax Credits
Katy Rabindran

Research & Development Tax Credits are a valuable benefit for many research-intensive companies and not dependent on shareholders or similar stakeholders.

Our expert speaker, Katy Rabindran will take us through the key issues and help guide you as to whether R&D tax credits could be a valuable financial support for your life sciences business.

Katy Rabindran
Senior Manager at BDO

2:10^PM - 3:10^PM

Panel Discussion: HR & Talent • Future Proofing Your Business
Hsin Loke•Oliver Sexton•Matthew Shaw-Clark•Wendy Tindsley

Sponsored by Hays

This panel will focus on how important it is for a growing business to get their equality, diversity, and inclusion HR Strategy right from the start, and the impact this has will have on matters such as talent, growth, investment & internal/external value.

Hsin Loke
VP Finance and Operations at OMass Therapeutics
Oliver Sexton
Investment Director of UKI2S
Matthew Shaw-Clark
Director of Life Sciences at Hays Life Sciences
Wendy Tindsley
Innovation Director of Oxford Innovation

Agenda

Jonathan Rohll

Etleva Pashaj

Alex Blyth

Mustafa Djamgoz

William Finch

Peter Joyce

Salim Khakoo

Carlos Meca

Agnès Menut

Jon Moore

Clare Wareing

Tim Wilson

Gokhan Yahioglu

Jennifer Schranz

Nara Daubeney

Lorenzo Errichelli

Dean Hum

Jon Rees

Jack Scannell

Myles Dakin

Chris Marlein

Caroline Barelle

Rebecca Ashfield

Mario Caria

Antoine Carlhian

Edward Hodgkin

Joe Illingworth

Kirsty Semple

Bart Wuurman

Felix Faupel

Denise Kelly

Pierre Belichard

Tomas De wouters

Benjamin Hadida

James McIlroy

Mike Romanos

Felix Faupel

Charlotte Deane

Vibhor Gupta

Ben Holland

Debora Lucarelli

Louwai Muhammed

Manish Patel

Michelle Teng

Guy Griebel

Laurent Pradier

Jenny Barnett

Peter Hamley

Farid Khan

David Reynolds

Mo Shahid

Helen Fletcher

Douglas Thomson

Peter Jackson

Anna Obolensky

Frederic GARZONI

Will Wjinberg

Huw Jones

Tim Haines

Harry Destecroix

Jason Mellad

Emma Palmer Foster

George Freeman

James Tumbridge

Laia Crespo

Sinclair Dunlop

Simon Haworth

Ian Oliver

Jasper Bos

Catherine Beech

Antimo Fiorillo

Javier Jimenez

Emma Tinsley

Helen Underwood

Rafaèle Tordjman

Alison Dennis

Rose Adedeji

John Catravas

Charles Macdowell